Masarykuv Onkologicky Ustav
Masarykuv Onkologicky Ustav is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Masarykuv Onkologicky Ustav?
The 2026-10-09 snapshot links Masarykuv Onkologicky Ustav to 2 distinct CTIS trials. Recorded services include 68Ga-PSMA-11 preparation and administration, diagnostic via PET/CT, Radiotherapy. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Masarykuv Onkologicky Ustav?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Masarykuv Onkologicky Ustav conducted?
The linked trials record locations in 14 countries, including Austria, Belgium, Czechia, Germany, Netherlands. These are trial locations, not confirmed office locations or countries where Masarykuv Onkologicky Ustav delivered services.
What can this page tell me about Masarykuv Onkologicky Ustav's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Masarykuv Onkologicky Ustav. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Masarykuv Onkologicky Ustav